Abstract Early detection of cancer is vital to improved overall survival rates. At present, evidence is accumulating for the clinical value of detecting occult tumor cells in peripheral blood, plasma, and serum specimens from cancer patients. Both molecular and cellular approaches, which differ in sensitivity and specificity, have been used for such means. Circulating tumor cells and extracellular nucleic acids have been detected within blood, plasma, and sera of cancer patients. As the presence of malignant tumors are clinically determined and/or confirmed upon biopsy procurement-which in itself may have detrimental effects in terms of stimulating cancer progression/metastases-minimally invasive methods would be highly advantageous to the diagnosis and prognosis of breast cancer and the subsequent tailoring of targeted treatments for individuals, if reliable panels of biomarkers suitable for such an approach exist. Herein, we review the current advances made in the detection of such circulating tumor cells and nucleic acids, with particular emphasis on extracellular nucleic acids, specifically extracellular mRNAs and discuss their clinical relevance.
Introduction
Breast cancer is the second most frequently diagnosed cancer after skin cancer in the US, with only lung cancer responsible for more female cancer-related deaths [1] . In recent times gene expression studies and immunohistochemical analyzes have classified breast cancer into five major subtypes depending on the presence or absence of hormone receptor expression and certain other markers.
Perou et al. [2] intrinsic classification defines these subtypes as basal-like breast cancers which largely correspond to estrogen receptor (ER) negative, progesterone receptor (PR) negative, and HER-2 negative tumors (i.e., triple negative); luminal A (mostly ER positive and lowgrade histologically); luminal B (also mostly ER positive, can express low levels of hormone receptors and often are high grade); HER-2 (also referred to as ErbB2) positive (show amplification and high expression of HER-2 gene); and triple negative tumors. Some basal-like cancers have high expression of cytokeratin (CK) 5, but as of yet, immunohistochemical methods of defining basal-like cancers are not well established due to logistical difficulties of performing many IHC markers in a clinical setting [3] . A final subtype is defined as normal breast-like tumors.
Breast cancer recurrence
The majority of breast cancer deaths are as a result of recurrent metastatic disease. Metastatic disease occurs as a result of a series of steps involving multiple host-tumor interactions [4] (reviewed by Gilbey et al. [5] ). Primary tumor cells, whether they possess genetic mutations or have certain stem-like properties, grow aberrantly and may eventually detach, intravasate into the lymphatic and/or blood systems, before developing into secondary disease A. M. Friel Á C. Corcoran Á L. O'Driscoll (&) [4] . In breast cancer when tumor cells enter the lymphatic system, they travel to the sentinel nodes in the axilla and intercostal spaces before entering the bloodstream and subsequent progression to other organs [4] . In addition, tumor cells can disseminate directly through the blood to distant organs [6] . The detection and characterization of such cells would be an advantage in the identification of patients who are at risk of disease recurrence and the subsequent tailoring of individualized treatments.
The need and settings for breast cancer biomarkers Breast cancer diagnosis is often merely confirmatory when a growth/lump is detected in the breast by the patient. Although mammography has greatly aided diagnosis for some patients (unfortunately it is dependent on mammography availability and also on the individual's age/breast tissue density, etc.), currently breast cancer is typically diagnosed on tissue biopsy. Individuals referred to a breast clinic (generally by their primary care physician) include those who will be diagnosed with breast cancer and those with a benign/harmless lump, e.g., fibroma. However, due to the lack of a blood/serum diagnostic test, biopsies must be assessed for all referred individuals. This often results in unnecessary delays for those with breast cancer, who need prioritising; unnecessary worry for those who have a benign condition; and an overall strain on clinics and health care systems. As outlined above, gene expression analysis of tumor tissue has enabled breast cancer sub-classification into five major sub-types. This information is relevant, as treatment options (e.g., hormone, Trastuzumab, chemotherapy) depends on the tumor sub-type. However, panels of biomarkers are urgently needed for earliest possible detection of breast cancer, for prognosing outcome and for predicting response to therapy, so as to determine those who require treatment versus over-treating those who do not, and to ensure that those who would benefit from neooadjuvant/adjuvant therapy receive the treatment to which they are most likely to respond. Undoubtedly, minimally invasive blood/serum tests that could aid in breast diagnosis (to triage individuals) and in tumor sub-typing (ensure optimal treatment selection) would contribute to timely, personalized management of those referred to the breast clinic; ultimately contributing to improved quality of life and overall survival.
No single biological biomarker can accurately detect breast cancer. The heterogeneity of breast cancer tumors is well documented. This is evident by the detection of tumor-initiating capabilities of certain cell populations, based on expression levels of specific surface markers (CD44 ? , CD24 -/low , EpCAM ? , Lineage -) [7] . These cells-often termed cancer stem cells, due to certain stemlike characteristics they share with normal stem cells-are capable of reconstituting tumors in vivo. Such cancer stem cells have also been documented in a variety of different tumors including ovary (CD44 ? /CD117 ? ) [8] , (CD133 ? ) [9, 10] , and endometrium [11] .
Circulating tumor cells
Circulating tumor cells (CTCs) are defined as tumor cells circulating in the peripheral blood of patients, shed from either the primary tumor or from its metastases. The presence of solid tumor-derived cells in peripheral blood was first reported in 1869 [12] . CTC detection in breast cancer, based on expression of specific cell surface markers, is a fast emerging area of research with efforts focusing on detection of early metastatic disease. The development of a suitable assay has proven difficult due to the heterogeneous nature of CTCs. In general, there are two main methods for their detection. These are based on cytometric and nucleic acid manipulation. Both methods generally require an enrichment step to increase sensitivity of the assay. This step is based on either detection of specific surface markers using immuno-selection and/or on morphological features, such as cell size or density. Each of the several methods available to detect CTCs have distinct advantages and disadvantages. We present a brief description of the most clinically relevant assays used, including their associated advantages/disadvantages. Readers are directed towards a recent article for an in-depth review on technical and statistical considerations for CTC analyzes in the clinic [13] .
Detection methods of circulating tumor cells

CellSearch
Ò
The most established application of CTC analysis so far is based on CTC counts (CellSearch Ò System) and has been FDA approved for monitoring metastatic breast cancer [14] . This semi-automated technology combines both positive (epithelial cell adhesion molecule: EpCAM; using ferrofluid nanoparticles coated with anti-EpCAM antibodies) and negative (anti-CD45) selection. The enriched CTC population is then immunostained for specific markers and counted using a semi-automated fluorescence microscope, i.e., the CellSpotter analyzer (Veridex; Johnson & Johnson). Thus, isolated CTCs are defined as EpCAM ? , CK ? , DAPI ? , and CD45 -. In metastatic breast cancer an initial and first follow-up CTC count of C5 per 7.5 ml blood is predictive of shorter progression free survival and overall survival [15, 16] . While a CTC count C5 per 7.5 ml blood at any time during therapy is indicative of a rapid disease progression and mortality [17] . A further study highlights the importance of use of the CellSearch Ò system as an independent prognostic factor for early breast cancer relapse [18] . However, at present (based on the most recent publication) the American Society of Clinical Oncology (ASCO) does not recommend the use of CTC detection for diagnosis or clinical management decisions in breast cancer [19] . Similarly even though the CellSearch Ò test is FDA approved, ASCO does not recommend its use for clinical decisions in metastatic breast cancer until further validation proves otherwise. While it is recognized that this method is highly sensitive, reproducible, commercially available, FDA approved, and has the capability of distinguishing between viable/non-viable cells, limitations include: usage of EpCAM to capture CTCs may miss some EpCAM -tumor cells, result in false positives (due to expression of the same antigens on non-tumor cells), the multiple enrichment/processing steps may also result in loss of CTC detection and no further processing of the CTC samples is possible.
CTC-microchip
Other immuno-selection approaches for CTC capture include the CTC-microchip. The CTC-chip is a microfluidics platform based on the interaction of target CTCs with antiEpCAM-coated microposts under precisely controlled laminar flow conditions, without requiring any pre-labeling or processing of specimens [20] . This gives the opportunity for further analysis of the captured, unfixed CTCs. Furthermore, good enrichment (98% cell viability) has been reported with this approach [21] . Limitations, similar to CellSearch Ò , include the fact that only EpCAM-positive CTCs are captured in this way, the technology is not available commercially and clinical validation has yet to be achieved. So, while many of these formats of CTC analysis have great potential, it is likely that their routine incorporation into clinical laboratories is some way off and that their future application will be as a component of a panel of assays; rather than the definitive method. . This study associated the positive presence of DTCs, at follow-up, with disease recurrence and highlighted the presence of persistent DTCs as being indicative of failed primary therapy, while suggesting that secondary adjuvant therapy may be of benefit in these patients. With regards to characterization of DTCs following therapy, HER-2 positive cells have been detected in breast cancer DTCs even though the corresponding primary tumor was HER-2 negative, implying that targeted therapy may be beneficial for such patients [43] . These studies provide compelling evidence of the importance of the initial detection and any subsequent detection and characterization following therapy of DTCs in BM of breast cancer patients. At present ASCO does not recommend the assessment of BM for DTC in the management of patients with breast cancer. In reality, the sampling of BM DTCs for monitoring purposes may not generally be feasible in a typical breast clinic and so DTC analysis is unlikely to become routine in the timeframe of some of the less-invasive analyzes (which involve more straightforward blood sampling) outlined in this review.
EPISPOT
Disseminated tumor cells
Circulating nucleic acids and cancer
Circulating nucleic acids are defined as extracellular nucleic acids (DNA or RNA) found circulating in the blood throughout the body. Such extracellular nucleic acids are thought to arise as a result of being secreted from cells; be it from normal cells, or malignant cells of primary or metastatic origin. The presence of circulating nucleic acids in plasma and serum has implications for minimally invasive diagnostic and predictive applications in benign and malignant conditions. Current terminology in literature for such nucleic acids include: circulating nucleic acids, cellfree nucleic acids and extracellular nucleic acids. For the purpose of this review we will refer to such nucleic acids as extracellular nucleic acids.
Evidence of extracellular nucleic acids in cancer Extracellular nucleic acids, specifically extracellular DNA (exDNA), were first described in human plasma/serum by Mandel [61] . Similarly the presence of exRNA is well documented in sera/plasma from patients presenting with breast [62] [63] [64] and colon cancers [65, 66] .
Origin of extracellular nucleic acids
Questions remain as to the origin of extracellular nucleic acids, which can be found as free nucleic acids [67] , bound to a cell's surface via proteins with specialized nucleic acid binding properties [68] [69] [70] , complexed with proteolipids [71, 72] and within apoptotic bodies [73] . Studies have shown that they (DNA and RNA) can be released spontaneously from cells [74, 75] . However, the exact mechanism of release from normal cells and tumor cells remains to be fully elucidated.
Anker et al. [76] and Jahr et al. [77] proposed tumor cell apoptosis/necrosis, apoptosis or lysis of CTCs, and/or active release from tumor cells as possible release mechanisms. RNA-proteolipid complexes/microvesicles/exosomes have been isolated from sera of cancer patients [78, 79] and from cancer cell lines [80, 81] . The importance of communication between tumor cells and their environment through fusion of shed membrane microvesicles to neighboring cells was discussed by Ratajczak et al. [82] . These microvesicles, 30-100 nm in diameter [83] , can be shed from the cell surface or via inward budding of endosome membranes [84] . Once released into extracellular space these microvesicles are termed exosomes [85] and may be involved in trans-cellular signaling [86] , transfer of membrane receptors, proteins, mRNA/microRNA [87] , and organelles (e.g., mitochondria) between cells. Another role may be in the delivery of infectious and toxic agents (e.g., chemotherapeutic drugs) into cells [88] (reviewed by [82] ).
It is thought the contents of exosomes depend on their cell of origin [78] ; those derived from immune cells having immunostimulatory and anti-tumor effects in vivo [89] , while those derived from tumor cells accelerate tumor growth [78, 90] and invasiveness [91, 92] . Additionally, the RNA contained within exosomes is amplifiable; suggesting protection from RNase degradation by the exosome membrane [78] . Other groups have also demonstrated that serum/plasma RNAs in cancer patients are contained and protected in membrane bound structures [73, 93] , (reviewed by [94] ). Although circulating exosomes have been identified as having potential diagnostic relevance in some cancer types (including ovarian cancer [95] ; glioblastomas [78] ; and lung cancer [95] ), the prevalence and clinical relevance of exosomes in sera from breast cancer patients has yet to be elucidated.
Extracellular RNAs and CTCs associated RNAs in breast cancer
More recent efforts have focused on the identification of possible biomarkers for diagnostic purposes in autoimmune and malignant diseases. In breast cancer exRNAs have been documented by a number of research groups [63, [96] [97] [98] . We present the most documented studies on cell-free exRNAs and CTC associated RNAs.
Cytokeratin 19
Cytokeratins belong to a family of over 20 related polypeptides located in the cytoskeleton of various epithelial cells. Their main role is to provide cellular structure and integrity. They are classified into two types: acidic type I (CK9-CK20) and basic type II (CK1-CK8) [99] . Epithelial cells are targets of caspase-mediated proteolysis during apoptosis [100] . CK19 is cleaved by caspase 3 and soluble fragments (CYFRA 21-1), released into extracellular space, have been detected in sera of cancer patients [62, 101] and reportedly do not correlate with that of full-length CK19 mRNA [62] .
Initially, Silva et al. [96] identified CK19 mRNA in plasma of breast cancer patients (49%) in comparison to healthy controls (20%). On evaluation of clinicopathological parameters (including patient age, tumor size, histopathological type and stage, lymph node metastases, ER and PR status, proliferative index) with molecular data, two parameters (tumor size and proliferative index as determined by Ki-67 IHC) were associated with the presence of plasma CK19 mRNA. As the recurrence rate in stage I and stage II breast cancer is between 10-20% and 40-65%, respectively [102] , it was proposed that the high proportion of patients in the study with early stage cancer (stage II) and showing positivity for CK19 mRNA expression, might be an indicator of patient clinical outcome and recurrence. Ninety percent of patients with detectable plasma CK19 mRNA were also positive for CK19-positive CTCs. Although the authors are unclear as to the significance of this finding, they suggest that shedding rates of nucleic acids from CTCs with metastatic potential may be higher than from tumor cells, i.e., that the exRNA identified in their study may have originated from CTCs.
More recent reports have demonstrated the prognostic significance of CK19 mRNA-positive CTCs in patients with early stage breast cancer [103] [104] [105] . Studies that investigated the prognostic value of CTCs/DTCs at the time of completion of adjuvant therapy [42, 106, 107] showed that the detection of DTCs [42, 108] and CTCs [106] after the completion of chemotherapy is associated with an unfavorable clinical outcome [103, 105] ; further reviewed by Ignatiadis et al. [109] . In keeping with this work suggesting diagnostic and prognostic relevance for CK19, more recently full-length CK19 has been detected in bone marrow specimens from breast cancer patients and is associated with the presence of overt metastases and poor survival rates [110] .
Human telomerase reverse transcriptase
Telomeres are a sequence of repetitive DNA located at the end of linear chromosomes where they serve to prevent the chromosome end from being recognized as DNA doublestranded breaks. Telomerase is the ribonucleoprotein reverse transcriptase complex that maintains telomere length and is reactivated in 90% of cancers [111] . It is composed of two subunits: an RNA component (TERC) and a telomerase reverse transcriptase (TERT). TERT is generally not expressed in most differentiated somatic cells; therefore, telomerase activity is absent. TERT is the major determinant for activation of telomerase. Absence of telomerase activity leads to a progressive shortening of telomeres and cellular senescence. However, reactivation of telomerase is considered a crucial step for malignant cells to become immortal.
Detection of hTERT expression either in plasma [65, 112] , peripheral blood mononuclear cells [113] or by IHC in primary tumors [114] has been identified as diagnostic for prostate, colon, esophageal cancers, and paragangliomas, respectively. In terms of breast cancer, Chen et al. [97] identified hTERC and hTERT mRNA in primary tumors and sera of breast cancer patients presenting with invasive lobular carcinoma and invasive ductal carcinoma. Of the specimens analyzed, hTERT was identified in 25% of sera and 94% of primary tumors, while hTERC was identified in 28% of sera and 94% of primary tumors. hTERC or hTERT was not detected in sera from control subjects or patients presenting with benign disease. No correlation was found between patient age, tumor size, tumor grade or the presence of nodal metastases.
A more recent study identified hTERT mRNA-positive CTCs [115] . Shen et al. [115] 2009 reported hTERT expression in 59.6% of patients presenting with breast cancer in comparison to healthy volunteers (0%) and benign controls (0%). Importantly, detection of hTERT mRNA significantly correlated with the TNM (internationally used tumor, node, metastases staging system) stage and lymph node metastasis, with hTERT present in 24.2, 67.9, 80.0, and 100% of patients with a TNM stage of I, II, III, and IV, respectively. In conjunction with hTERT, this group also investigated expression of survivin and hMAM (human mammaglobin), and reported improved sensitivity and specificity with all three biomarkers correlating to TNM stage. The authors conclude that the use of peripheral blood would be advantageous in clinical monitoring of early stage hematogenous spreading that may further develop into breast cancer metastasis or recurrence.
Bmi-1
Polycomb group (PcG) proteins are implicated in embryonic development and oncogenesis [116] [117] [118] . PcG protein expression is often dysregulated in several types of cancer and strongly correlates with an invasive and/or metastatic phenotype [119, 120] . Bmi-1 (PcG protein B lymphoma Mo-MLV insertion region 1 homolog), was initially identified as an oncogene cooperating with c-myc in the development of murine pre-B-cell lymphomas [121] . Bmi-1 plays an essential role in maintaining the self-renewal of normal and malignant human mammary stem cells [122] . Over-expression of Bmi-1 is reported and correlated to poor clinical prognosis in solid tumors of breast [123] , lung [124] and colon [125] cancers; to name but a few. Silva et al. [98] investigated Bmi-1 mRNA expression in plasma of a cohort of patients presenting with various subtypes and stages of breast cancer. Bmi-1 mRNA was detected in 43.2% of breast cancer specimens and also in 55% of healthy controls. However, expression levels were significantly higher in patients presenting with cancer versus the healthy controls. Upon correlation of gene expression with clinical-pathological features of the primary tumor (including vascular invasion, tumor subtype/stage, ER and PR receptor status, p53 status, HER-2 status, proliferative status), higher Bmi-1 levels were associated with p53-positive immunostaining and PR-negative status. Importantly, the presence of plasma Bmi-1 mRNA was found to be associated with poorer survival at a more advanced clinical stage suggesting plasma Bmi-1 to be a potential surrogate biomarker of poor prognosis that could be analyzed minimally invasively.
Human mammaglobin
Human mammaglobin (MGB) belongs to the uteroglobin/ Clara cell protein family of small epithelial secretory proteins [126, 127] and was discovered by Watson and Fleming [128] in their isolation of sequence fragments that were abundantly expressed in breast tumors relative to normal breast tissue. The MGB1 promoter contains a polyoma enhancer-related motif which is associated with over-expression of HER-2 in breast cancer [129] . Two isoforms of MGB have been reported. These are mammaglobin 1 (also referred to as MGB1, mammaglobin A, SCG2A2) and mammaglobin 2 (MGB2, mammaglobin B, SCGB2A1). Most research on the use of MGB as a potential diagnostic biomarker in cancer has focused on MGB1, although there are reports of high levels of MBG2 mRNA and protein being associated with well (Grade 1) and moderately (Grade 2) differentiated endometrioid endometrial tumors [130] .
Initially, Watson and Fleming [131] detected MGB1 expression in several breast carcinoma cell lines but not in primary breast stromal cells nor in immortalized luminal ductal breast cell lines. They concluded that MGB1 expression is mammary-specific, as MGB1 was expressed exclusively in mammary epithelial cells. It was since reported, however, that MGB1 is expressed at the mRNA and protein level in tumors of the endometrium, ovary, and cervix [132] . Watson and Fleming [131] also reported that primary breast carcinomas over-expressed MGB1 relative to normal breast tissue specimens, with approximately 50% of breast carcinoma cell lines and metastatic breast tumors analyzed exhibiting high levels of MGB1 mRNA. This over-expression did not appear to correlate with histology, tumor grade, tumor stage, or ER/PR status. A more recent study reported high MGB1 levels in primary breast cancers to be indicative of a less aggressive tumor phenotype and correlating with the expression of ER and PR, low Ki-67 labeling and absence of nodal invasion [133] . There has, so far, been no reported documentation of circulating transcripts of MGB1, however, MGB1 protein has been detected in sera of breast cancer patients [134, 135] .
Recent efforts have focused on the detection of MGB1 in peripheral blood [136] [137] [138] as a diagnostic biomarker of metastatic disease. Mikhitarian et al. [139] used a panel of biomarkers (CK19, MUC1, MGB1, EpCAM, HER-2, prolactin inducible protein) in their investigation of a possible correlation between mRNA expression in peripheral blood CTCs, bone marrow DTCs and clinicopathological indicators (tumor type, TNM, ER/PR status, HER-2 status, age, and race). Their main finding was the lack of correlation between biomarker positivity in CTCs and tumor type and/or biomarker status of axillary lymph nodes. However, a significant association was reported between biomarker positivity in CTCs and tumor grade (grade II-III versus grade I), with this association holding true for expression of MGB1 mRNA alone. As this was an interim report of an ongoing study, the clinical significance in terms of overall survival and disease-free survival remain to be seen.
Cyclin D1
Cyclin D1 is a cell cycle regulator. It is induced by a variety of factors, such as epithelial growth factor, hormones and oncogenic signals and its over-expression is one of the most commonly observed alterations in cancer [140] . In breast cancers, cyclin D1 is over-expressed by 30-50% of tumors [140] and is documented as being predictive of poor clinical outcome [141] . García et al. [63] investigated whether plasma mRNA from breast cancer patients is related to disease-free survival and overall survival. Presence of cyclin D1 plasma mRNA was significantly associated with non-responsive patients following treatment after relapse. Additionally the authors reported a trend towards a significant relation between reduced overall survival rates and cyclin D1 presence. No association was detected between cyclin D1 plasma mRNA presence and disease-free survival.
HER-2
Approximately 25% of breast cancers over-express HER-2. Trastuzumab, a monoclonal antibody against the HER-2 receptor is the only approved targeted agent for treatment of HER-2 over-expressing cancers. However, not all patients respond to treatment and some develop resistance. The most frequent approach to measure HER-2 levels is by FISH, IHC, and ELISA. The extracellular domain of HER-2 can be proteolytically cleaved from the cell membrane and this domain can be measured in peripheral blood. Patients with HER-2 positive breast cancer have high serum HER-2 levels, which correlate positively with the number of metastatic sites and are indicative of disease recurrence [142] . While the presence and thus relevance of HER-2 mRNA in serum or plasma has yet to be investigated, detection of HER-2 mRNA-positive CTCs in blood specimens from patients with operable breast cancer have been reported as prognostic of unfavorable outcome, in terms of both relapse-free survival and overall survival [143] .
As detailed above, research to date indicates that mRNAs (including CK19, TERT, Bmi-1, MGB, cyclin D1, and HER-2, to name but a few) exist in the systemic circulation-either freely or sequestered in microvesicles or exosomes. Undoubtedly, such mRNAs have potential as breast cancer biomarkers. However, while these studies have ''proven-the-principle'' and opened up an opportunity for biomarker searches that was initially considered to be irrelevant due to the high levels of RNase enzymes in this environment, we believe that more extensive studies are now needed to identify and validate the most relevant panels of mRNAs in large cohorts of relevant cases.
MicroRNAs in breast cancer
MicroRNAs (miRNAs) are a family of endogenous small noncoding RNA molecules, of 19-28 nucleotides in length (reviewed: [144] [145] [146] ). Over the past 2 years, since the first report of circulating microRNAs (miRNAs) associated with diffuse large B-cell lymphoma [147] , circulating miRNAs have been reported in studies of a range of other cancer types. Specifically, in prostate cancer, serum miR-141 level was found to distinguish metastatic prostate patients (n = 25) from age-matched controls [148] . Similarly, miR-25 and miR-223 were reported as non-small cell lung cancer specific following their analysis in sera from 152 patients compared to 75 healthy volunteers [149] . Circulating miRNAs, albeit in exosomes, have also been reported to have potential as biomarkers for ovarian cancer [150] and for glioblastoma [78] . Studies of circulating miRNAs associated with breast cancer have been limited to date. In our pilot study, in addition to circulating mRNAs [64] , we detected circulating miRNAs (including miR-141 and miRNA-195) to be present at significantly higher levels (P \ 0.001) in serum from patients recently diagnosed with breast cancer compared to age-and gender-matched healthy volunteers (as yet unpublished). In agreement with our findings, mi-195 and let-7a have recently been reported as at significantly higher levels in blood from breast cancer patients, compared to healthy volunteers [151] .
Therefore, while studies of circulating miRNAs are still in their infancy, analyzes performed thus far suggested that these miRNAs-whether freely existing or enclosed in exosomes/microvesicles-may prove to have great potential as biomarkers for many cancers, including breast cancer. Due to their short sequences and stability (e.g., can be routinely assessed in formalin-fixed paraffin-embedded tissue and apparently can withstand many rounds of freezethawing when in solution) it is possible that miRNAs may have certain advantages over mRNAs as circulating biomarkers. Alternatively, a biomarker panel could conceivably include single or multiplex co-analysis of both types of RNA molecules; possibly offering some advantages over protein biomarker analysis. Now that their potential usefulness in this setting has been established, more extensive studies are essential in order to establish how best to exploit our understanding of circulating RNA molecules in the interest of breast cancer patients.
Limitations of blood-based biomarkers and future directions
Although research into potential cancer biomarkers has been ongoing for many years, the actual number of markers used in clinical settings remains limited [152] [153] [154] . The main reason being the discovery and development of useful biomarkers pose many challenges, with several factors contributing to the slow rate of biomarker development [19, 155] . The ASCO published a report on recommendations for the use of tumor markers in breast cancers. They report a lack of validation of potential biomarkers as being a major obstacle in the development of new biologics or treatment strategies for patients. Areas that contribute to this problem include non-uniform procurement, processing and storage of specimens, differences in technologies used, non-standardized assays/non-validated equipment-all contributing to lack of study reproducibility, inappropriate statistical analyzes and insufficient patient specimen numbers. In addition, while some studies may show promising results, the overall lack of sufficient high-quality studies coupled with a lack of consistent data results in their omission from use as clinical markers for breast cancers [19] .
To date, ASCO has recommended eight tumor biomarkers for breast cancer-all of which are proteins, i.e., CA 15-3 and CA 27.29, carcinoembryonic antigen (CEA), ER, PR, HER-2, urokinase plasminogen activator (uPA), and plasminogen activator inhibitor (PAI)-1. CA 15-3, CA 27.29, and CEA are biomarkers for monitoring; ER, PR and HER-2 are biomarkers for treatment planning; and uPA and PAI-1 are biomarkers for recurrent risk prediction [19] . While these are the only markers ASCO approved for clinical use, ASCO does not discourage the use of other novel or innovative approaches in the context of clinical trials (e.g., I-SPY 2 trial [156] ). For future advancement in clinically useful biomarkers, well-designed, collaborative studies involving the inclusion of specimens-procured, processed, and analyzed using standard operating procedures-from large cohorts of consenting patients and healthy volunteers (for example, in Ireland such studies are possible, as facilitated by the All Ireland Irish Clinical Oncology Research Group (ICORG), as well as through international collaborations) should help in identifying and validating biomarkers panels which can be translated to the clinic, in the interest of cancer patients.
In 2001, Pepe et al. [157] defined five phases of biomarker development for early detection of cancer, i.e., (1) preclinical exploratory studies; (2) clinical assay development; (3) retrospective longitudinal repository studies; (4) prospective screening studies; and (5) cancer control studies assessing impact of screening on reducing the burden of disease. While all breast cancer biomarker studies are not aimed at diagnosis, the same overall strategy is very relevant to consider. An open mind should be kept as to what the final portfolio of any given biomarker panel may include. So far, there are no proven advantages of one molecule type over another with regards to their potential as biomarkers. Although, historically, focus has mainly been on proteins and more recently CTCs, results emerging from exploratory studies suggest that RNAs-which are proving to be reproducibly detected and can be amplified using a multiplex approach (thus minimizing the amount of specimen required for analysis) will form members of useful breast cancer biomarker panels. To date, what could possibly be best described as proof-of-concept studies have been reported on RNAs (mRNAs and miRNAs) as biomarkers. Relative to protein research, however, we believe that this field of research is still in its infancy and should now be much more extensively explored. While this has yet to be established, it is probable that optimal sensitivity and specificity will include a combination of mRNA, miRNA, protein-and possibly also CTC-analysis from a patient's blood specimen. It is our view that it is only through carefully designed research efforts and systems that are patient-orientated and collaborative, that the development of robust panels of such biomarkers and associated reliable assays will translate to the clinic to contribute to improvements in personalized treatment, quality of life and survival for breast cancer patients.
Conclusion
Breast cancer is the second leading cause of cancer-related deaths in the US and the most common cancer in women in the western world. The need for rapid methods for early detection of breast cancer, prognosing outcome, and predicting response to treatment-by analyzing CTCs or specific circulating protein and/or nucleic acids-would greatly aid current treatment modalities. Additionally, such biomarkers could potentially be used for continual monitoring of tumor response to treatment allowing for a change in treatment regime if needed, i.e., tailoring treatment for the individual.
In the past, the development of suitable assays to detect cancer cells has proven difficult due to the heterogeneous nature of breast cancer tumors. Current advances in molecular profiling have enabled certain surface biomarkers and gene expression patterns to be used for identification of breast tumor cells and their associated genes. As the majority of breast cancer deaths are as a result of recurrent metastatic disease, which may be caused by spread of CTCs/DTCs resulting from tumor resection, a minimally invasive method for cancer detection and monitoring would be clinically highly advantageous. In addition such a system has the potential to allow for early detection screening of people at increased risk of cancer. For the most part, biomarkers are not yet ready for routine use due to challenges in their clinical validation for breast cancer detection/diagnosis, prognosis and response to treatment prediction. However, advancing on the recent exciting studies reviewed here, current and future research focussing on the identification of diagnostic, prognostic and/or predictive circulating nucleic acids/CTCs has immense importance clinically to the development and improvement of current diagnostic and therapeutic options for breast cancer patients. 
